Form 8-K NovoCure Ltd For: Jul 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NovoCure Ltd. (NVCR) PT Raised to $44 at Mizuho Securities
July 27, 2018 8:44 AM EDTMizuho Securities raised its price target on NovoCure Ltd. (NASDAQ: NVCR) to $44.00 (from $32.00) while maintaining a Buy rating.
Analyst Difei Yang commented, "NovoCure reported 2Q18 results yesterday. Net revenue of $61.5 mil beat FactSet consensus of $59.5 mil while EPS of $(0.17) was slightly below consensus of... More
